Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2025)

Historic Income from Continuing Operations for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Income from Continuing Operations fell 6932.76% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 5482.52%. This contributed to the annual value of -$297.4 million for FY2024, which is 4218.87% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Income from Continuing Operations of -$130.1 million as of Q3 2025, which was down 6932.76% from -$115.7 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$22.9 million for Q1 2021, and its period low was -$130.1 million during Q3 2025.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$53.4 million (2023), whereas its average is -$60.8 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Income from Continuing Operations plummeted by 2023.15% in 2023 and then tumbled by 6932.76% in 2025.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Income from Continuing Operations stood at -$30.8 million in 2021, then tumbled by 48.18% to -$45.7 million in 2022, then decreased by 22.53% to -$55.9 million in 2023, then crashed by 43.69% to -$80.4 million in 2024, then tumbled by 61.85% to -$130.1 million in 2025.
  • Its Income from Continuing Operations stands at -$130.1 million for Q3 2025, versus -$115.7 million for Q2 2025 and -$96.6 million for Q1 2025.